NDA 011265 · Ani Pharms
Promethazine Hydrochloride and Dextromethorphan Hydrobromide
Dextromethorphan Hydrobromide, Promethazine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Sep 16, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1957
Dec 3, 1957
Approved uses
3
Original approval plus efficacy supplements
Registered trials
206
29 Phase 3, 17 recruiting
FAERS reports
3
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution should not be used in pediatric patients less than 2 years of age because of the potential for fatal respiratory depression. Postmarketing cases of respiratory depression, including fatalities, have been reported with use of promethazine in pediatric patients less than 2 years of age. A wide range of weight-based doses of promethazine have resulted in respiratory depression in these patients. Caution should be exercised when administering promethazine to pediatric patients 2 years of age and older. It is recommended that the lowest effective dose of promethazine be used in pediatric patients 2 years of age and older and concomitant administration of other drugs with respiratory depressant effects be avoided.
What it is approved for
From the label in effect Aug 8, 2025.
INDICATIONS AND USAGE Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 11, 1988 Supplement 19 · Efficacy
- Apr 2, 1984 Supplement 13 · Efficacy
- Dec 3, 1957 Original approval · Type 4 - New Combination
1 products under this application
- PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE · DEXTROMETHORPHAN HYDROBROMIDE 15MG/5ML; PROMETHAZINE HYDROCHLORIDE 6.25MG/5ML · SYRUP, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Dextromethorphan Hydrobromide" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Evaluation of S (+) - Ketamine in AdultsPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04837170 · 12,000 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2022
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: Postoperative Pain; Adults; Anesthesia
- Safety and Efficacy Evaluation of S (+) - Ketamine in ChildrenPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04834427 · 3,000 participants (planned) · Start Apr 20, 2022 · Primary completion Dec 1, 2024
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: S-ketamine; Esketamine; Acute Pain and 6 more
Sites: Beijing, China
- Combined Therapy of Methadone and DextromethrophanPivotal-lookingStatus unknown
National Cheng-Kung University HospitalAcademic, hospital or other
NCT01189097 · 1,500 participants (planned) · Start Apr 2008 · Primary completion Mar 2011
Drug: Dextromethorphan; Dextromethorphan · For: Opioid Abuse
Sites: Tainan, Taiwan
- Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypePivotal-lookingTerminated
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02446132 · 1,197 participants · Start Nov 13, 2015 · Primary completion Sep 6, 2024
Drug: AVP-786 · For: Agitation in Patients With Dementia of the Alzheimer's Type
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 227 sites in all
- Open-Label Safety Study of AXS-05 in Subjects With DepressionPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04039022 · 876 participants · Start Jul 8, 2019 · Primary completion Oct 23, 2020
Drug: AXS-05 (dextromethorphan and bupropion) oral tablets · For: Major Depressive Disorder; Treatment Resistant Depression; Depression
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bellflower, California · 51 sites in all
- Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07766655 · 705 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 2027
Drug: AXS-05 (dextromethorphan-bupropion); Bupropion and 1 more · For: Smoking Cessation
Sites: Phoenix, Arizona; Little Rock, Arkansas; Lemon Grove, California · 28 sites in all
- Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.Pivotal-lookingCompleted
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
NCT03738917 · 668 participants · Start Feb 1, 2019 · Primary completion Nov 30, 2021
Drug: Dextromethorphan 15 milligrams; Ipratropium Bromide 20Micrograms Inhaler · For: Acute Bronchitis
Sites: Badalona, Spain; Balaguer, Spain; Barcelona, Spain · 12 sites in all
- Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)Pivotal-lookingCompleted
Avanir PharmaceuticalsIndustry
NCT00056524 · 600 participants (planned) · Start Feb 2003 · Primary completion Jun 2007
Drug: AVP-923 · For: Alzheimer's Disease; Stroke; Parkinson's Disease and 1 more
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 39 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- colectomy1
- intestinal obstruction1
- neuropathy peripheral1
- product use in unapproved indication1
- somnolence1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E, Ellis C, Brassington R, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects.
Aylward M, Maddock J, Davies DE, et al. · Eur J Respir Dis 1984 · Clinical Trial, Comparative Study
- Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
Zimmermann T, Schlenk R, Pfaff G, et al. · Arzneimittelforschung 1995 · Clinical Trial
- Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
Lötsch J, Rohrbacher M, Schmidt H, et al. · Pain 2009 · Clinical Trial
- Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers.
Demirbas S, Reyderman L, Stavchansky S · Biopharm Drug Dispos 1998 · Clinical Trial, Controlled Clinical Trial
- Design and evaluation of taste masked dextromethorphan hydrobromide oral disintegrating tablets.
Malladi M, Jukanti R, Nair R, et al. · Acta Pharm 2010 · Clinical Trial
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.